<?xml version="1.0" encoding="UTF-8"?>
<p id="Par32">Although it is hypothetically possible nowadays to interfere with every step of the infectious cycle of respiratory tract viruses (from viral attachment, viral entry and uncoating, translation, replication, and onward to virus release), only a few approaches have met with success with RV thus far. There is only a limited number of agents that interact with the RV attachment to the cell or uncoating of the viral RNA that have been tested in clinical trials (pleconaril, amantadine, rimantadine) [
 <xref ref-type="bibr" rid="CR71">71</xref>]. Regrettably, their clinical applicability is continuously questioned due to adverse events (pleconaril, vapendavir) or drug resistance (amantadine, rimantadine) [
 <xref ref-type="bibr" rid="CR66">66</xref>].
</p>
